If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its ...

CRISPR Therapeutics (CRSP) is back in focus after upsizing its convertible note offering to US$550 million, a key funding move tied directly to the company’s gene editing ambitions and CASGEVY ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...

A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly for life, according to a small early study released Saturday. The study, which ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.